eSense-Lab Limited provided an update on the research conducted in the Central Virology Lab of the Ministry of Health in Sheba Medical Center. Further tests have been conducted under the Company's research agreement with MOH, for the testing of TRP-ENV in combination with low level ethanol, against HCov-OC43 (a weak strain of human corona virus which represents an accepted surrogate to evaluate activity of substances against SARS-CoV-2 (the virus that causes the disease called COVID-19)). This study was conducted as part of the Company's commercial goal to develop a superior, organic, dominant sanitiser product that provides added protection against bacteria and viruses, while reducing its ethanol content (which is known for its harmful side effects to the skin and its flammability risks). The Stage 2 ­ Part 1 Trial follows a conclusive result previously announced on 27 November 2020, which showed no superior anti-viral contribution of TRP-ENV to ethanol <70%. Accordingly, the Stage 2 ­ Part 1 Trial was conducted in the presence of a lower ethanol level than was previously tested, which resulted in encouraging anti-viral activity of TRP-ENV in the presence of ethanol <<70%, which was superior to the relevant ethanol <<70% alone. The second part of these tests included an evaluation of anti-viral properties of a new proprietary terpene blend developed for BetterAir Ltd. BetterAir is a commercial company that already sells a unique bacterial based air and surface sanitising technology. The proprietary terpene blend, termed TRP-BIO, was specifically designed to be tolerated by the unique BetterAir bacterial population. The aim of Stage 2 - Part 2, which was also undertaken by MOH, was to generate feasibility data that would bridge into a commercial negotiation between ESE and BetterAir. The study resulted in potential anti-viral activity of TRP-BIO in the presence of BetterAir's bacteria, which eSense considers may provide a potential future opportunity to enter into a commercial agreement with BetterAir.